Regeneron, Sanofi Expand Immunology Alliance With $1B Upfront Payment
Sanofi and Regeneron Pharmaceuticals are expanding their immunology alliance, adding four next-generation antibody programs. Regeneron will receive $1 billion upfront and up to $7 billion in potential milestone payments.
Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) are broadening their long-running immunology alliance with four next-generation, long-acting antibody programs added to the partnership. Under the agreement, Regeneron will receive $1 billion upfront and could receive up to another $7 billion in potential milestone payments.